BLOG

NK Cell Therapy vs Immune Checkpoint Inhibitors: A Patient Guide

Published 2026.10.09 7 min read

Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.

When people search for cancer “immunotherapy,” they often find very different treatments described under the same word. Immune checkpoint inhibitors, cell therapies, and vaccines all aim to involve the immune system, but they work in different ways and sit in different places in the healthcare system. This article explains how NK cell therapy differs from checkpoint inhibitors, so that international patients can ask better questions before a consultation at Grand Green Osaka Umekita Clinic or any other medical institution.

The short answer: related goals, different mechanisms

Both approaches are connected to the immune system, but they are not the same kind of treatment and they should not be treated as interchangeable. Immune checkpoint inhibitors are drugs that act on signals which can restrain immune cells. NK cell therapy, as offered at our clinic, is a cell-based approach in which a patient’s own natural killer cells are collected from a standard blood draw, activated and expanded at a specialized facility, and returned by intravenous infusion.

In other words, one approach works on the signals that regulate immune cells, while the other focuses on increasing the number and activity of a particular type of immune cell. Neither description should be read as a promise of results. Whether any immune-based treatment is suitable depends on the type and stage of the cancer, prior treatments, general health, and a doctor’s individual assessment.

How immune checkpoint inhibitors work

Immune cells carry molecular “brakes” that help prevent the immune system from attacking healthy tissue. Some cancers are thought to make use of these brakes to avoid immune attack. Checkpoint inhibitors are medicines designed to block certain brake signals, allowing immune cells to respond more actively. They are prescribed for specific cancer types under regulatory approval, usually within standard medical care, and their use is guided by clinical guidelines and the treating oncologist.

Because these are drugs that change how the immune system is regulated, they can cause immune-related side effects in some patients. Anyone receiving or considering such a drug should discuss eligibility and monitoring with their oncology team. This article does not evaluate those medicines, and nothing here suggests choosing between them and any other option.

How NK cell therapy works

NK (natural killer) cells are innate immune cells that circulate in the body and can recognize and attack abnormal cells, including cancer cells and virus-infected cells, without waiting for instructions from other immune cells. NK cell activity is thought to decline with age, stress, and the effects of cancer itself. The idea behind NK cell therapy is to return NK cells to the body in greater numbers and with higher activity, with the aim of supporting weakened immune function.

The process begins with a standard blood draw. The cells are then activated and expanded at a licensed cell processing facility and returned through an intravenous drip. Because the cells come from the patient, the therapy is described as autologous, and the risk of rejection is considered low. Temporary fever or fatigue can still occur, and all risks and side effects should be reviewed with a physician before starting.

Key differences patients often ask about

Several practical differences help explain why the two approaches should be considered separately.

What is being used: a drug that acts on immune signals, versus a patient’s own cultured NK cells.
Where it fits: checkpoint inhibitors are generally part of standard cancer care for specific indications, whereas NK cell therapy in Japan is provided as a self-pay (non-insured) treatment under the Act on the Safety of Regenerative Medicine.
How it is delivered: both involve medical supervision, but NK cell therapy requires a blood collection step and a cell preparation period before infusion.
What to ask: eligibility, expected benefits and limits, possible side effects, and total cost are specific to each treatment and each patient.

It is also important to be realistic about evidence. Research on NK cells in cancer is active, but published findings vary by cancer type and study design, and results from one study should not be generalized to every patient. NK cell therapy is not a replacement for standard treatment, and it should not be presented as a cure.

Can NK cell therapy be considered alongside standard treatment?

Some patients consider NK cell therapy alongside surgery, chemotherapy, or radiation therapy. Whether combining it with a particular regimen makes sense is a medical decision. If you are already being treated by an oncologist, whether in Japan or in your home country, it is reasonable to tell that doctor about your interest and to share relevant records. At our clinic, coordination with the institution providing your standard treatment is possible.

Patients who have been told that a checkpoint inhibitor or another approved therapy is appropriate for them should not delay or stop that treatment on the basis of general information found online. Any plan should be agreed with the physicians responsible for your care.

Questions to bring to a consultation in Osaka

Grand Green Osaka Umekita Clinic, located in the Umeda area of Osaka, offers consultations about NK cell therapy and provides information pages for international patients in several languages. Preparing questions in advance can make a consultation more productive. Useful topics include:

Whether your cancer type and current condition make NK cell therapy something a doctor would consider.
How it would relate to treatments you are receiving or have received, including any immunotherapy drugs.
What the number of treatments, schedule, and total cost would be, since this is self-pay care outside insurance.
What risks, side effects, and limitations apply to your situation.
How the clinic communicates with your home doctors and how language support is arranged.

Fees, risks, side effects, and eligibility must be confirmed through a doctor’s examination. We encourage you to read the treatment information page and the fees and FAQ sections before contacting the clinic, and to treat the answers you receive as part of a broader decision made together with your own physicians.

Summary

Immune checkpoint inhibitors and NK cell therapy both relate to the immune system, but they differ in what they use, how they work, and where they sit within the Japanese healthcare system. NK cell therapy uses a patient’s own activated and expanded cells, is provided as self-pay treatment under Japan’s regenerative medicine framework, and does not replace standard cancer care. If you are considering it, prepare your medical records and questions, speak with your own oncologist, and confirm eligibility, costs, and risks with a doctor at the clinic.

Two immune-based approaches

Checkpoint drugs

Medicines acting on immune signals
Standard care for some cancers
Discuss with your oncologist

NK cell therapy

Your own expanded NK cells
Self-pay, regenerative medicine act
Suitability confirmed by a doctor

This diagram is a conceptual summary of the article content

Learn more about NK Cell Therapy

References

Supervising Physician

Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic

Hidenori Shimada

Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.

* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.

Back to article list › Back to NK Cell Therapy ›